Pacific Channel has led a $2 million investment in Upstream Medical Technologies to accelerate the development of innovative cardiac diagnostic solutions.

Information on the Target

Upstream Medical Technologies specializes in the development of innovative frontline diagnostic tests for cardiac disorders. Each year, millions of individuals present to hospital emergency departments with chest pain; currently, about two-thirds of these patients can be quickly evaluated with existing biomarkers. However, approximately one-third of these patients fall into a category known as the 'grey zone,' complicating their rapid triage. It is essential for ED doctors to have access to prompt and precise diagnostic tools to identify patients who require immediate medical intervention versus those who can be safely discharged.

The company recently announced significant advancements in its research and development through a $2 million investment, which will facilitate the testing of a novel biomarker—provisionally titled Marker C. This biomarker aims to aid in the swift and accurate detection of patients at risk for heart attacks presenting with symptoms of heart disease.

Industry Overview in New Zealand

The healthcare industry in New Zealand is characterized by a strong emphasis on innovation and research, particularly in the medical technology sector. Recent years have seen an increase in investment directed towards health tech